MonicaCLuchiMD

Rheumatology • Philadelphia, PA

Physician

Join to view full profile

Dr. Luchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luchi's full profile

Already have an account?

Office
38th & Market St
8th Floor
Philadelphia, PA 19104
Phone+1 215-662-4333

Education & Training

Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1987 - 1991
Northeast Ohio Medical UniversityClass of 1987

Certifications & Licensure

PA State Medical License 1992 - 2024
NJ State Medical License 1994 - 2001
NY State Medical License 1989 - 2000
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease Start of enrollment: 2007 Sep 17
Completed
Phase 3
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis Start of enrollment: 2008 Oct 28
Completed
Phase 2
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs Start of enrollment: 2009 May 01
Completed
Phase 2
Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed Start of enrollment: 2021 Apr 01
Withdrawn
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis.
Soochan Kim, Eunhwa Ko, Hwan Geun Choi, Daekwon Kim, Monica Luchi
Journal of Translational Autoimmunity. 2023-01-01
4 citations
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Charles Peterfy, Julie C DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone
The Journal of Rheumatology. 2019-01-15
213 citations
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone, Peter C. Taylor, E. Drescher, Douglas E Schlichting, Scott D. Beattie
Annals of the Rheumatic Diseases. 2015-02-01

Press Mentions

Anti-Inflammatory Drugs Demonstrate Pathway SavvyJuly 7th, 2022
Chutes & Ladders—FDA's Top Two Vaccine Leaders to Depart in the Fall as Questions Loom over Booster ShotsSeptember 3rd, 2021
Brickell Biotech Nabs Autoimmune, Inflammatory Program from Voronoi for up to $320M in BiobucksSeptember 1st, 2021
Join now to see all

Other Languages

Spanish, German